ReNeuron encouraged by progress in stroke and RP treatments


(, ) has announced Catherine Isted will be joining the board as Chief Financial Officer effective 11 October, 2021.

Isted, who holds a first-class chemistry degree and is also a chartered accountant, is joining from Oxford Biomedica PLC, where she is currently part of the finance leadership team heading up the corporate development and investor relations functions.

“Catherine has an excellent knowledge of the healthcare sector and is highly skilled in equity capital markets, M&A [mergers & acquisitions] and strategic business development,” said Ian Ross, the chairman of ReNeuron.

Isted has also held research analyst and equity sales positions in the healthcare teams at (), ABN AMRO, Nomura and Peel Hunt – experience that will be “incredibly valuable”, according to the company’s chief executive officer, Olav Hellebo.


Please enter your comment!
Please enter your name here